← Leaderboards
Rui Chang
Albert Einstein College Of Medicine
$4,628,013
Attributed
$12,135,081
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,135,081 · 4
By mechanism
R01$8,208,114 · 2
RF1$2,312,496 · 1
R56$1,614,471 · 1
Top collaborators
- Roberta Diaz Brinton5 shared
- Lisa Mosconi5 shared
- Yvonne Margaret Saenger5 shared
- Elizabeth M Bradshaw3 shared
- Tracy L Young-Pearse3 shared
- Takahisa Kanekiyo2 shared
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- Yvonne Margaret Saenger$3,946,350
- Derek Major Huffman$7,446,355
- Evripidis Gavathiotis$9,805,575
- Jelena Pavlovi$1,944,190
- Michael Aschner$17,443,221
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposMolecularSystems BiologyS DiseaseImageBiological MarkersNuclearNetwork ModelsData SetTreatment EfficacyS Disease ModelPathway InteractionsCellsTherapeutic TargetAnimal ModelMulti-Scale ModelingBioinformaticsMetabolomicsBaseGenomicsGenomic DataGenotypeMessenger RnaClinical Data
Grant awards (15)
Applying pathomics to establish a biosignature for aggressive skin melanoma$607,163
R01 · FY2025 · CA
Applying pathomics to establish a biosignature for aggressive skin melanoma$584,380
R01 · FY2024 · CA
Applying pathomics to establish a biosignature for aggressive skin melanoma$616,736
R01 · FY2023 · CA
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,130,295
R01 · FY2022 · AG
Applying pathomics to establish a biosignature for aggressive skin melanoma$1
R01 · FY2022 · CA
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,107,464
R01 · FY2021 · AG
Applying pathomics to establish a biosignature for aggressive skin melanoma.$693,456
R01 · FY2021 · CA
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,134,417
R01 · FY2020 · AG
Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease$777,659
R56 · FY2020 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,141,341
R01 · FY2019 · AG
Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease$836,812
R56 · FY2019 · AG · contact PI
Building Novel Predictive Networks for high-throughput, in-silico Key Driver Prioritization to Enhance Drug Target Discovery in AMP-AD and M2OVE-AD$383,750
RF1 · FY2019 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,192,861
R01 · FY2018 · AG
Building Novel Predictive Networks for high-throughput, in-silico Key Driver Prioritization to Enhance Drug Target Discovery in AMP-AD and M2OVE-AD$1,710,225
RF1 · FY2017 · AG · contact PI
Building Novel Predictive Networks for high-throughput, in-silico Key Driver Prioritization to Enhance Drug Target Discovery in AMP-AD and M2OVE-AD$218,521
RF1 · FY2017 · AG · contact PI